iTeos Therapeutics, Inc. (ITOS)
- Previous Close
7.50 - Open
7.54 - Bid 7.62 x 100
- Ask 7.71 x 100
- Day's Range
7.42 - 7.68 - 52 Week Range
4.80 - 18.75 - Volume
96,821 - Avg. Volume
399,432 - Market Cap (intraday)
293.177M - Beta (5Y Monthly) 1.43
- PE Ratio (TTM)
-- - EPS (TTM)
-3.05 - Earnings Date Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.33
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
www.iteostherapeutics.comRecent News: ITOS
View More
Performance Overview: ITOS
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ITOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ITOS
View MoreValuation Measures
Market Cap
287.05M
Enterprise Value
-228.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.07
Price/Book (mrq)
0.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-14.54%
Return on Equity (ttm)
-23.68%
Revenue (ttm)
35M
Net Income Avi to Common (ttm)
-130.81M
Diluted EPS (ttm)
-3.05
Balance Sheet and Cash Flow
Total Cash (mrq)
520.37M
Total Debt/Equity (mrq)
0.90%
Levered Free Cash Flow (ttm)
-47.05M
Research Analysis: ITOS
View MoreResearch Reports: ITOS
View MoreWhat does Argus have to say about ITOS?
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $8.00
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $9.00
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetWhat does Argus have to say about ITOS?
ITEOS THERAPEUTICS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice Target